Top Biotech Short Squeeze Stocks

by Fred Fuld III

Last week was the worst performing of the year for stocks, so far. Especially for the biotech stocks.

This may create a buying opportunity for biotech stocks that are heavily shorted.

Do short squeeze stocks actually go up?

On August 22, 2022, I posted an article about meme related short squeeze stocks, and pointed out Bed Bath and Beyond (BBBY) after it had its big run-up. In exactly one week after the article was posted, the stock jumped by more than 43%.

Another stock that was mentioned was Intercept Pharmaceuticals, Inc. (ICPT), which increased by almost 5% in just two days.

The stock with the biggest short ratio (days to cover), at 14.3 back then, was Heron Therapeutics, Inc. (HRTX). It rose by 9.5% in three days.

When you short a stock, it means that your goal is to make money from a drop in the price of a stock. Technically, what happens is that you borrow shares of a stock, sell those shares, then buy back those shares at a hopefully lower price so that those shares can be returned. This all happens electronically, so you don’t actually see all the borrowing and returning of shares; it just shows up on your screen as a negative number of shares.

Short sellers can be profitable, but sometimes when the stock moves against them, and begins to rise, the short sellers jump in right away to buy shares to cover their positions, creating what is called a short squeeze. When a short squeeze takes place, it can cause the share prices to increase fast and furiously. Any good news can trigger the short squeeze.

Some traders utilize this situation by looking for stocks to buy that may have a potential short squeeze. Here is what a short squeeze trader should take into consideration:

Short Percentage of Float ~ The float is the number of freely tradable shares and the short percentage is the number of shares held short divided by the float. Amounts over 10% to 20% are considered high and potential short squeeze plays.

Short Ratio / Days to Cover / Short Interest Ratio -This is probably the most important metric when looking for short squeeze trades, no matter what you call it. This is the number of days it would take the short sellers to cover their position based on the average daily volume of shares traded. This is a significant ratio as it shows how “stuck” the short sellers are when they want to buy in their shares without driving up the price too much. Unfortunately for the shortsellers, the longer the number of days to cover, the bigger and longer the squeeze.

Short Percentage Increase ~ This is the percentage increase in in the number of short sellers from the previous month.

The following are some heavily shorted tech stock that may be worth considering.

CompanySymbolShort % of FloatShort % ChangeShort Interest Ratio
NovavaxNVAX43% 0% 4.5
ImmunitybioIBRX29%6%14
PMV PharmaceuticalsPMVP29%-4%16.5
SpringWorks TherapeuticsSWTX30%-2%16.5

The second stock on the list, Immunitybio (IBRX), which develops  therapies and vaccines that amplify the immune system to defeat cancers and infectious diseases, has about 29% of its float shorted, an increase of 6% over last month.

The short interest ratio is 14, which means that it would take the short sellers 14 days to cover their position, based on recent average volume.

Just keep in mind that just because a stock has good earnings ratios and is heavily shorted, doesn’t mean that the stock will go up, especially in a bear market. Also, stocks that are significantly shorted may be shorted for a reason.

Disclosure: Author didn’t own any of the above at the time the article was written.

Stocks That Made New Highs on Friday

By Fred Fuld III

Yesterday, Friday, August 19, 2022, in spite of the stock market being down, there were several stocks that actually made new highs.

Many stock traders believe that when a stock makes a new high, it is bullish for the stock.

Plus if a stock makes new highs on a day when the stock market drops, then that is very positive for the stock and extremely bullish.

So yesterday, the S&P 500 was down 55, the Dow Jones Industrial Average was down 292, and the NASDAQ was down an incredible 260, which was a drop of more than 2%.

In spite of that, there were a select few companies that did rise on Friday.

The following is a group of the new high stocks, most of which are biotech companies.

Axsome Therapeutics (AXSM)

NL Industries (NL)

ADMA Biologics (ADMA)

Intercept Pharmaceuticals (ICPT)

Supernus Pharmaceuticals (SUPN)

Artesian Resources (ARTNA)

Keep in mind that some of these stock are very low cap and therefore very speculative.

Check out the related articles of interest

10 BDC Stocks Paying Over 8%

4 Equity REITs Paying High Yields Over 10%

DisclosureL Author didn’t own any of the above at the time the article was written.

Stocks in the Race for the COVID-19 Vaccine

by Nkem Iregbulem

Since the start of the global coronavirus pandemic, various U.S. biotechnology companies have entered the race to develop COVID-19 therapies and vaccines. To aid and accelerate the development, manufacturing, and distribution of a COVID-19 vaccine, the U.S. government initiated a public-private partnership called Operation Warp Speed. This partnership hopes to deliver 300 million doses of a successful vaccine by January of next year. To achieve this goal, Operation Warp Speed selected eight companies with promising vaccine candidates to receive government funding — namely, Johnson & Johnson, AstraZeneca-University of Oxford, Pfizer-BioNTech, Moderna, Merck, Vaxart, Inovio, and Novavax.

Investing in biotechnology companies with a foot in the vaccine race may be financially worthwhile if certain candidates prove successful in their efforts to develop a safe and effective COVID-19 vaccine. In fact, the stock prices for many of these companies fighting against the coronavirus pandemic are already trading near record highs. Your options include Moderna (MRNA), Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), and Sorrento (SRNE). All of these stocks are traded on the NASDAQ exchange.

Your first option is Moderna (MRNA), a biotech company primarily focused on discovering and developing therapeutics and vaccines based on messenger RNA, or mRNA. These technologies are designed to handle infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular disease. In January of this year, Moderna announced it had started developing its own COVID-19 vaccine, named mRNA-1273. In late July, the company’s vaccine candidate entered Phase 3 trials with the launch of a 30,000-subject trial. This progress puts Moderna ahead of many other companies in the race for the vaccine. Founded in 2010 and headquartered in Massachusetts, Moderna has a market cap of $27.51 billion and does not pay a dividend. Its stock has a price-to-sales ratio of 474.82 and a price-to-book ratio of 16.76. As of its most recent quarter, Moderna has $1.22 billion in total cash and $151.84 million in total debt. With its revenue decreasing each fiscal year since 2018, the company faces a negative 3-year revenue growth rate of -17.80%.

Another vaccine stock to pay attention to is Inovio Pharmaceuticals (INO), a biotechnology company that discovers, develops, and commercializes synthetic DNA medicines and vaccines to treat and protect against HPV-associated diseases, infectious diseases, and cancers. The company is developing its very own DNA-based COVID-19 vaccine candidate, INO-4800. Inovio’s INO-4800 is currently in Phase 1 trials in the U.S., and a Phase 2/3 trial is expected to begin this summer. Founded in 1983 and based in Plymouth Meeting, Pennsylvania, Inovio has a market cap of $3.07 billion and does not pay a dividend. Its stock has a high price-to-sales ratio of 786.00 and price-to-book ratio of 16.67. As of its most recent quarter, Inovio has $270 million in total cash and $98.52 million in total debt. Inovio has seen decreasing revenue each fiscal year since 2017, contributing to its negative 3-year revenue growth rate of -51.19%.

You might also consider Novavax (NVAX) — founded in 1987 and headquartered in Gaithersburg, Maryland. The late-stage biotechnology company focuses on discovering, developing, and commercializing vaccines to prevent a wide variety of infectious diseases. Some of its current vaccine candidates are geared towards influenza and RSV. In January, it announced its intention to develop a vaccine — called NVX-CoV2373 — to treat coronavirus. Novavax has a market cap of $9.15 billion and does not pay a dividend. Its stock trades at 34.13 times forward earnings and has a high price-to-sales ratio of 238.50. As of its most recent quarter, the company has $237.36 million in total cash and $331.87 million in total debt. Novavax has a negative 5-year revenue growth rate of -9.45% but a better 3-year revenue growth rate of 6.72%.

Vaxart (VXRT) is another biotech company in the race for a coronavirus vaccine. Founded in 2004 and based in South San Francisco, the clinical-stage company discovers, develops, and commercializes orally administered recumbent vaccines to treat infected patients around the world. This past January, Vaxart announced the development of its COVID-19 vaccine candidate: a tablet vaccine. Its other candidates include influenza, norovirus, and RSV vaccines.The company has a market cap of $992.76 million and does not pay a dividend. Its stock has a high price-to-sales ratio of 44.56 and a price-to-book ratio of 32.74. As of its most recent quarter, Vaxart has $29.86 million in total cash and $2.13 million in total debt. The company faces a negative 5-year revenue growth rate of -29.71% but enjoys a 3-year revenue growth rate of 1.69%.

Finally, you might also consider Sorrento (SRNE), a clinical-stage biotechnology company that focuses on developing immunotherapies for cancers, autoimmune, inflammatory, and neurodegenerative diseases. The company has teamed up with Mount Sinai Health System to develop an antibody therapy — named COVI-SHIELD — to target the COVID-19 infection. This product would deliver three antibodies that would serve as a “protective shield” against the virus. Founded in 2006 and headquartered in San Diego, Sorrento has a market cap of $2.05 billion and does not pay a dividend. It trades at 1.71 times forward earnings. Its stock has a high price-to-sales ratio of 46.05 and a price-to-book ratio of 20.28. As of its most recent quarter, the company has $21.9 million in total cash and $255.01 million in total debt. Sorrento enjoys a 5-year revenue growth rate of 52.39% and an even better 3-year revenue growth rate of 56.81%.

Let’s hope we get a vaccine and cure soon.

Disclosure: Author owns MRNA.